{"id":36898,"date":"2019-04-04T09:18:19","date_gmt":"2019-04-04T16:18:19","guid":{"rendered":"https:\/\/cjnotebook.com\/?p=36898"},"modified":"2019-04-04T09:18:19","modified_gmt":"2019-04-04T16:18:19","slug":"three-pharmaceutical-companies-agree-to-pay-122-million-for-kickback-allegations","status":"publish","type":"post","link":"https:\/\/cjnotebook.com\/?p=36898","title":{"rendered":"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations"},"content":{"rendered":"<p style=\"text-align: center;\"><strong><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">MASSACHUSETTS<\/span><\/strong><\/p>\n<figure id=\"attachment_31812\" aria-describedby=\"caption-attachment-31812\" style=\"width: 300px\" class=\"wp-caption alignleft\"><a href=\"https:\/\/cjnotebook.com\/consumer-reports-many-meds-americas-love-affair-prescription-medication\/consumer-reports-pills\/\" rel=\"attachment wp-att-31812\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-31812 size-medium\" src=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills-300x219.jpeg\" alt=\"\" width=\"300\" height=\"219\" srcset=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills-300x219.jpeg 300w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills-278x202.jpeg 278w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg 750w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption id=\"caption-attachment-31812\" class=\"wp-caption-text\">Photo: Consumer Reports<\/figcaption><\/figure>\n<div class=\"field field--name-field-pr-body field--type-text-long field--label-hidden\">\n<div class=\"field__items\">\n<div class=\"field__item even\">\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013 agreed to pay $122 million to resolve allegations that they violated kickback laws, according to officials<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The company each allegedly violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program or ChampVA copays for their own products, through independent foundations that the companies used as mere conduits, officials said.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">When a Medicare beneficiary obtains a prescription drug covered by Medicare, the beneficiary may be required to make a partial payment, which may take the form of a copayment, coinsurance, or a deductible (collectively \u201ccopays\u201d). Similarly, under ChampVA, patients may be required to pay a copay for medications. \u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Congress included copay requirements in the Medicare program, in part, to serve as a check on health care costs, including the prices that pharmaceutical manufacturers can demand <\/span>for<span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\"> their drugs. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The Anti-Kickback Statute prohibits a pharmaceutical company from offering or paying, directly or indirectly, any remuneration \u2014 which includes money or any other thing of value \u2014 to induce Medicare or ChampVA patients to purchase the company\u2019s drugs. This prohibition extends to the payment of patients\u2019 copay obligations.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u201cPharmaceutical companies undercut a key safeguard against rising drug costs when they create assistance funds to serve as conduits for the companies to subsidize the copays of their own drugs,\u201d said Assistant Attorney General Jody Hunt of the Department of Justice\u2019s Civil Division. \u201cThese enforcement actions make clear that the government will hold accountable drug companies that directly or indirectly pay illegal kickbacks.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u201cWe are committed to ensuring that pharmaceutical companies do not use third-party foundations to pay kickbacks masking the high prices those companies charge for their drugs,\u201d said U.S. Attorney Andrew E. Lelling. \u201cThis misconduct is widespread, and enforcement will continue until pharmaceutical companies stop circumventing the anti-kickback laws to artificially bolster high drug prices, all at the expense of American taxpayers.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Jazz and Lundbeck each entered five-year corporate integrity agreements (<\/span>CIAs<span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">) with OIG as part of their respective settlements. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The <\/span>CIAs<span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\"> require the companies to implement measures, controls, and monitoring designed to promote independence from any patient assistance programs to which they donate. In addition, the companies agreed to implement risk assessment programs and to obtain compliance-related certifications from company executives and Board members.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u201cThese kickback schemes harm Medicare and the public,\u201d said Gregory E. Demske, Chief Counsel to the Inspector General. \u201cOIG CIAs<\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">, such as those with Jazz and Lundbeck, are<\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0designed to reduce future risks to patients and taxpayer-funded programs. OIG decided not to require a CIA with Alexion because it made sweeping and fundamental organizational changes following the bad conduct. The changes included hiring a new eight-member executive leadership team and changing half of the members of its Board of Directors. In addition, 40 percent of Alexion\u2019s employees are new and the company relocated its corporate headquarters.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u201cThese settlements demonstrate the FBI\u2019s commitment to safeguard the Medicare program and ensure that patients receive treatment solely based on their medical needs,\u201d said Joseph R. Bonavolonta, Special Agent in Charge of the Federal Bureau of Investigation, Boston Field Division. \u201cNot only did these companies undermine a program that was set up to assist patients in decreasing the cost of their drugs, but they threatened the financial integrity of the Medicare program to which we all contribute and on which we all depend.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u201cKickback schemes undermine the integrity our nation\u2019s healthcare system, including healthcare benefits administered by the U.S. Department of Veterans Affairs,\u201d said Special Agent-in-Charge Sean Smith, VA Office of Inspector General, Northeast Field Office. \u201cThe VA Office of Inspector General, along with our law enforcement partners, will continue to aggressively pursue these investigations and exhaust all efforts to uncover these schemes.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government\u2019s allegations in the three settlements being announced today are as follows:<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\"><b><u>Jazz<\/u><\/b><b>:\u00a0\u00a0<\/b>Jazz sells Xyrem, a narcolepsy medication with Gamma Hydroxybutyrate (GHB)\u2014a central nervous system depressant and controlled substance\u2014as its main active ingredient. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government alleged that, in 2011, Jazz asked a foundation to create a fund that would pay the copays of Xyrem Medicare patients and that the foundation agreed to establish a \u201cNarcolepsy Fund,\u201d to which Jazz became the sole donor. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government alleged that Jazz knew that, although Xyrem accounted for a small share of the overall narcolepsy market, the fund almost exclusively used Jazz\u2019s donations to pay copays for Xyrem and required non-Xyrem patients on competing products to obtain a denial letter from another assistance plan before helping them. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government further alleged that, in conjunction with establishing this fund, Jazz made Medicare patients ineligible for Jazz\u2019s free drug program and instead referred Xyrem Medicare patients to the foundation, enabling Jazz to generate revenue from Medicare and induce purchases of the drug, rather than continuing to provide these patients with free drugs. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Meanwhile, Jazz raised the price of Xyrem by over 150 percent from 2011 through the end of the relevant time period.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Jazz also sold Prialt, an injectable severe chronic pain medication. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government alleged that Jazz asked the same foundation to create a fund ostensibly to assist patients with the co-pays of any severe chronic pain drugs, but which, in practice, almost exclusively paid Prialt Medicare copays. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Shortly after creating the fund, the foundation allegedly told Jazz that when severe chronic pain patients seeking assistance with other drugs contacted the foundation, it would refer them elsewhere. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government alleged that Jazz was also aware that the fund did not appear on the foundation\u2019s website, thereby minimizing the number of <\/span>non<span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">-Prialt patients seeking assistance from the fund. Jazz has agreed to pay $57 million to resolve the government\u2019s allegations.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\"><b><u>Lundbeck<\/u><\/b><b>:\u00a0\u00a0<\/b>Lundbeck sells Xenazine, the only drug that was approved to treat chorea associated with Huntington\u2019s disease until a generic version became available until 2015. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government alleged that Lundbeck was the sole donor and made millions in payments to a fund at a foundation that ostensibly provided financial support only for patients with Huntington\u2019s Disease. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">However, Lundbeck allegedly referred Xenazine patients with many other conditions to this foundation, which then paid the Xenazine copays for these unapproved uses from its Huntington\u2019s Disease Fund.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government further alleged that, in June 2014, after the foundation determined that its Huntington\u2019s Disease fund would no longer pay the copays of patients taking Xenazine for non-Huntington\u2019s disease uses, Lundbeck agreed to repurpose some of its prior donations to the Huntington\u2019s Disease fund to a \u201cgeneral fund\u201d at the foundation for the purpose of paying these patients\u2019 Xenazine copays, and made subsequent \u201cunrestricted\u201d payments to the foundation with the understanding that the foundation would use these payments to pay Xenazine copays for these same patients. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Lundbeck allegedly asked the foundation whether there was a \u201crisk\u201d that this practice would be viewed as not compliant with the foundation\u2019s HHS-OIG Advisory Opinion, and the foundation allegedly replied that \u201c[t]<\/span>hey<span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\"> don\u2019t know what we use the general fund for.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government also alleged that, at the time it was engaged in the foregoing conduct, Lundbeck had a policy of not permitting Medicare or ChampVA patients to participate in its free drug program for Xenazine, which was open to other financially needy patients, even if those Medicare or ChampVA patients could not afford their copays for Xenazine. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Instead, in order to generate revenue from Medicare and ChampVA and to induce purchases of Xenazine, Lundbeck allegedly referred financially needy non-Huntington&#8217;s<\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0Disease Xenazine patients to the foundation, which resulted in claims to Medicare and ChampVA to cover the cost of the drug. Lundbeck has agreed to pay $52.6 million to resolve the government\u2019s allegations.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\"><b><u>Alexion<\/u><\/b><b>:\u00a0\u00a0<\/b>Alexion sells Soliris, which, from Jan. 1, 2010, through June 30, 2016, was <\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0for certain uses to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The cost of Soliris, based upon its list price and indicated dosing recommendation, can be approximately $500,000 per year. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">The government alleged that Alexion made donations to a \u201cComplement-Mediated Disease\u201d (CMD) fund at a foundation to pay the Medicare copay obligations of patients taking Soliris and to induce those patients\u2019 purchases of Soliris. Alexion allegedly knew that the price it<\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0set for Soliris could pose a barrier to patients\u2019 purchases of it. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">In particular, the government alleged that Alexion approached the foundation in January 2010 to request that it create a fund to provide financial assistance to Soliris patients, including by paying patients\u2019 Soliris Medicare copays and other medical expenses for Soliris patients. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Over the next several months, Alexion and the foundation allegedly discussed the coverage parameters for the fund, including Alexion\u2019s desire that the foundation \u201cnot support a patient with any of these [CMD] diagnoses for other reasons tha[n] Soliris therapy.\u201d <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">After the fund opened, Alexion\u2014the sole donor to the fund\u2014allegedly understood that the foundation\u2019s provision of financial assistance to a patient was contingent on the patient taking Soliris. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Alexion allegedly noted internally that it needed to be diligent in letting the foundation know if a patient had stopped taking Soliris so that Alexion\u2019s donations would not be used on patients who were not starting or maintaining Soliris therapy.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Meanwhile, the government alleged that Alexion had a general practice of not permitting Medicare patients to participate in its free drug program, which was open to other financially needy patients, even if those Medicare patients could not afford their copays for Soliris. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Instead, in order to generate revenue from Medicare and induce purchases of Soliris, Alexion allegedly referred Medicare patients prescribed Soliris to the foundation, through the foundation\u2019s \u201creferral portal\u201d software. <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Allegedly, the \u201creferral portal\u201d reported information back to Alexion confirming those Soliris patients who were approved for copay<\/span><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0or other financial assistance from the foundation, and detailed the foundation\u2019s payments to them, which resulted in claims to Medicare to cover the cost of Soliris. Alexion has agreed to pay $13 million to resolve the government\u2019s allegations.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013 agreed to pay $122 million to resolve allegations that they violated kickback laws, according&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31812,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-36898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-u-s-department-of-justice"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations<\/title>\n<meta name=\"description\" content=\"MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cjnotebook.com\/?p=36898\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations\" \/>\n<meta property=\"og:description\" content=\"MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cjnotebook.com\/?p=36898\" \/>\n<meta property=\"og:site_name\" content=\"American Justice Notebook\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmericanJusticeNotebook\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-04T16:18:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"547\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Raul\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Raul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898\"},\"author\":{\"name\":\"Raul\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/person\\\/f5521baddca77b521f012298775186c0\"},\"headline\":\"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations\",\"datePublished\":\"2019-04-04T16:18:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898\"},\"wordCount\":1705,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/Consumer-Reports-pills.jpeg\",\"articleSection\":[\"U.S. Department of Justice\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cjnotebook.com\\\/?p=36898#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898\",\"name\":\"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/Consumer-Reports-pills.jpeg\",\"datePublished\":\"2019-04-04T16:18:19+00:00\",\"description\":\"MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cjnotebook.com\\\/?p=36898\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=36898#primaryimage\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/Consumer-Reports-pills.jpeg\",\"contentUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/Consumer-Reports-pills.jpeg\",\"width\":750,\"height\":547},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#website\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/\",\"name\":\"American Justice Notebook\",\"description\":\"&quot;Our liberty depends on the freedom of the press, and that cannot be limited without being lost.&quot; \u2014  Thomas Jefferson\",\"publisher\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cjnotebook.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#organization\",\"name\":\"American Justice Notebook\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/Justice-Scales.jpg\",\"contentUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/Justice-Scales.jpg\",\"width\":675,\"height\":231,\"caption\":\"American Justice Notebook\"},\"image\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmericanJusticeNotebook\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/person\\\/f5521baddca77b521f012298775186c0\",\"name\":\"Raul\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g\",\"caption\":\"Raul\"},\"description\":\"Raul Hernandez is a former journalist. He has worked as a newspaper reporter for more than 30 years at the El Paso Herald-Post, El Paso Times, Press Enterprise in Riverside, California and the Ventura County Star in California. He was a court reporter for more than 20 years.\",\"sameAs\":[\"https:\\\/\\\/cjnotebook.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations","description":"MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cjnotebook.com\/?p=36898","og_locale":"en_US","og_type":"article","og_title":"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations","og_description":"MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013","og_url":"https:\/\/cjnotebook.com\/?p=36898","og_site_name":"American Justice Notebook","article_publisher":"https:\/\/www.facebook.com\/AmericanJusticeNotebook","article_published_time":"2019-04-04T16:18:19+00:00","og_image":[{"width":750,"height":547,"url":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg","type":"image\/jpeg"}],"author":"Raul","twitter_misc":{"Written by":"Raul","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cjnotebook.com\/?p=36898#article","isPartOf":{"@id":"https:\/\/cjnotebook.com\/?p=36898"},"author":{"name":"Raul","@id":"https:\/\/cjnotebook.com\/#\/schema\/person\/f5521baddca77b521f012298775186c0"},"headline":"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations","datePublished":"2019-04-04T16:18:19+00:00","mainEntityOfPage":{"@id":"https:\/\/cjnotebook.com\/?p=36898"},"wordCount":1705,"commentCount":0,"publisher":{"@id":"https:\/\/cjnotebook.com\/#organization"},"image":{"@id":"https:\/\/cjnotebook.com\/?p=36898#primaryimage"},"thumbnailUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg","articleSection":["U.S. Department of Justice"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cjnotebook.com\/?p=36898#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cjnotebook.com\/?p=36898","url":"https:\/\/cjnotebook.com\/?p=36898","name":"Three Pharmaceutical Companies Agree to Pay $122 Million for Kickback Allegations","isPartOf":{"@id":"https:\/\/cjnotebook.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cjnotebook.com\/?p=36898#primaryimage"},"image":{"@id":"https:\/\/cjnotebook.com\/?p=36898#primaryimage"},"thumbnailUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg","datePublished":"2019-04-04T16:18:19+00:00","description":"MASSACHUSETTS Three pharmaceutical companies \u2013 Jazz Pharmaceuticals plc (Jazz), Lundbeck LLC (Lundbeck), and Alexion Pharmaceuticals Inc. (Alexion) \u2013","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cjnotebook.com\/?p=36898"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cjnotebook.com\/?p=36898#primaryimage","url":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg","contentUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2017\/08\/Consumer-Reports-pills.jpeg","width":750,"height":547},{"@type":"WebSite","@id":"https:\/\/cjnotebook.com\/#website","url":"https:\/\/cjnotebook.com\/","name":"American Justice Notebook","description":"&quot;Our liberty depends on the freedom of the press, and that cannot be limited without being lost.&quot; \u2014  Thomas Jefferson","publisher":{"@id":"https:\/\/cjnotebook.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cjnotebook.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cjnotebook.com\/#organization","name":"American Justice Notebook","url":"https:\/\/cjnotebook.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cjnotebook.com\/#\/schema\/logo\/image\/","url":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales.jpg","contentUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales.jpg","width":675,"height":231,"caption":"American Justice Notebook"},"image":{"@id":"https:\/\/cjnotebook.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmericanJusticeNotebook"]},{"@type":"Person","@id":"https:\/\/cjnotebook.com\/#\/schema\/person\/f5521baddca77b521f012298775186c0","name":"Raul","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g","caption":"Raul"},"description":"Raul Hernandez is a former journalist. He has worked as a newspaper reporter for more than 30 years at the El Paso Herald-Post, El Paso Times, Press Enterprise in Riverside, California and the Ventura County Star in California. He was a court reporter for more than 20 years.","sameAs":["https:\/\/cjnotebook.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts\/36898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36898"}],"version-history":[{"count":5,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts\/36898\/revisions"}],"predecessor-version":[{"id":36903,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts\/36898\/revisions\/36903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/media\/31812"}],"wp:attachment":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}